Projects per year
Personal profile
specialisation
Immunotherapy, cancer, inflammatory diseases, antibodies, immunology
Research interests
Since the start of her career Prof. dr. van Egmond has studied the function of antibodies, with emphasis on understanding the role of immunoglobulin A (IgA) in physiology and pathology. Her research also addresses (1) the contribution of abnormal antibody responses in chronic inflammation and autoimmunity and (2) monoclonal antibody therapy of cancer. Prof. dr. van Egmond’s research is highly translational and she has a cross appointment with the Department of Surgery and the Department of Molecular Cell Biology and Immunology at Amsterdam UMC, to facilitate the rapid progression of pre-clinical findings into clinical applications. Prof.dr. van Egmond is the spokeswoman of the Dutch Society for Immunology, and since the COVID-19 crisis she has an active role in providing information on the immune system and vaccines to the general public.
Collaborations and top research areas from the last five years
Projects
- 1 Active
-
FUCOSYLATED GLYCAN EPITOPES AS NOVEL IMMUNE CHECKPOINT MOLECULES IN COLORECTAL CANCER
van Vliet, S., van Kooyk, Y., van Egmond, M. & Hatinguais, R.
1/06/2023 → 31/05/2026
Project: Research
-
Targeting myeloid cells with bispecific antibodies as novel immunotherapies of cancer
Sewnath, CAN., Behrens, LM. & van Egmond, M., 19 Jul 2022, In: Expert Opinion on Biological Therapy. 22, 8, p. 983–995 13 p.Research output: Contribution to journal › Review article › Academic › peer-review
Open Access4 Citations (Scopus) -
Antagonizing FcαR1 (CD89) as treatment in IgA-mediated chronic inflammation and autoimmunity
van Delft, M. A. M., Aleyd, E., Mast, R. V. D., de Jong, N., Boon, L., Simons, P. J. & van Egmond, M., 2023, In: Frontiers in immunology. 14, p. 1118539 1118539.Research output: Contribution to journal › Article › Academic › peer-review
Open Access -
Cost-effectiveness of selective decontamination of the digestive tract to decrease infectious complications in colorectal cancer surgery: An analysis of the SELECT trial
the SELECT-trial group, 1 Dec 2023, In: European Journal of Surgical Oncology. 49, 12, p. 1-7 7 p., 107116.Research output: Contribution to journal › Article › Academic › peer-review
Activities
-
Dutch Cancer Foundation (External organisation)
Marjolein van Egmond (Member)
1 Jan 2024 → …Activity: Membership › Membership of board › Academic
-
Neutrophils and cancer immunotherapy
Marjolein van Egmond (Speaker)
22 Nov 2023Activity: Lecture / Presentation › Invited talk › Academic
-
Novel FcαRI Bispecific Antibody Immunocytokines for the Recruitment of Myeloid Effector Cells in Cancer Therapy
Marjolein van Egmond (Speaker)
14 Nov 2023Activity: Lecture / Presentation › Invited talk › Academic
-
Academic founder and consultant
Marjolein van Egmond (Consultant)
1 Jun 2023 → …Activity: Consultancy › Academic
-
Novel Bispecific Antibody Immunocytokines for the Recruitment of Myeloid Effector Cells in Cancer Therapy
Marjolein van Egmond (Speaker)
21 Jun 2023Activity: Lecture / Presentation › Invited talk › Academic
Press/Media
-
TV interview Tijd voor Max over immuuntherapie van kanker
2/11/2023
1 Media contribution
Press/Media: Press / Media
-
Interview tijdschrift ‘Kijk over immuuntherapie van kanker
1/11/2023
1 Media contribution
Press/Media: Press / Media
-
-
-